Yvonne Jones
Family · Millsboro, DENPI 1518507920
Payments from drug & device makers
Across 39 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$249
- Novo Nordisk$198
- Dexcom, Inc.$106
- Abbott$86
- Boehringer Ingelheim$67
- Sanofi-aventis U.S. LLC$44
- plus $280 from 11 others
What the payments were for
- Food & beverage$98796%
- Education$444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 9 | $249 |
| Novo Nordisk | 7 | $198 |
| Dexcom, Inc. | 1 | $106 |
| Abbott | 4 | $86 |
| Boehringer Ingelheim | 4 | $67 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Corcept Therapeutics | 1 | $40 |
| Radius Health, Inc. | 1 | $31 |
| Boston Scientific | 1 | $30 |
| BETA Bionics, Inc. | 1 | $30 |
| Bayer | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $17 |
| Amgen | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,031 in reported general payments places this provider in the 65th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 321 | $661,875 |
| JardianceEmpagliflozin | 267 | $422,196 |
| Tresiba Flextouch U-100Insulin Degludec | 251 | $207,361 |
| TrulicityDulaglutide | 104 | $201,773 |
| MounjaroTirzepatide | 134 | $170,955 |
| Tresiba Flextouch U-200Insulin Degludec | 87 | $125,018 |
| RybelsusSemaglutide | 57 | $119,851 |
| FarxigaDapagliflozin Propanediol | 57 | $82,247 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $62,182 |
| JanuviaSitagliptin Phosphate | 42 | $45,863 |
| Novolog FlexpenInsulin Aspart | 164 | $45,831 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $45,510 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $41,849 |
| Humalog Kwikpen U-100Insulin Lispro | 98 | $40,175 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $31,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $198 | $781,726378 claims |
| Boehringer IngelheimJardiance, Tradjenta | $67 | $446,469284 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $249 | $372,729238 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $44 | $41,84931 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $2,981188 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 523 family providers in Delaware.
Other family in Millsboro
- Nicole CaselliMillsboro$5K
- Lisa HohlMillsboro$4K
- Sean ForsythMillsboro$4K
- Mandi LahmanMillsboro$4K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.